NASDAQ:TCBPW TC Biopharm (TCBPW) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free TCBPW Stock Alerts $0.02 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.01▼$0.0452-Week Range$0.00▼$0.12Volume982 shsAverage Volume40,775 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesShort InterestSocial Media Get TC Biopharm alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About TC Biopharm Stock (NASDAQ:TCBPW)TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Read More TCBPW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCBPW Stock News HeadlinesJanuary 4, 2024 | msn.comTC BioPharm regains compliance with NasdaqJanuary 3, 2024 | marketwatch.comTC BioPharm Shares Drop After Half of Workforce Gets CutApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 3, 2024 | finance.yahoo.comTC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline EfficienciesDecember 19, 2023 | marketwatch.comTC BioPharm Shares Tumble After Offering Gets PricedDecember 13, 2023 | msn.comTC Biopharm plans to implement ADS ratio changeDecember 13, 2023 | finance.yahoo.comTC BioPharm Announces Plan to Implement ADS Ratio ChangeNovember 28, 2023 | msn.comTC BioPharm receives FDA approval for AML cell therapy trialApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.November 2, 2023 | marketwatch.comTC BioPharm Inks Trial-Management Deal With Fortrea Amid Cost CuttingNovember 2, 2023 | finance.yahoo.comTC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical TrialsOctober 30, 2023 | morningstar.comADRs End Higher; TC Biopharm PLC Climbs 19%October 25, 2023 | finance.yahoo.comTC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial RequirementsOctober 23, 2023 | markets.businessinsider.comTC BioPharm Announces Filing Of IND For TCB-008 - Quick FactsOctober 23, 2023 | finance.yahoo.comTC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AMLOctober 12, 2023 | finance.yahoo.comTC Biopharm (Holdings) Plc (TCBPW)September 27, 2023 | finance.yahoo.comTC BioPharm to Present at the LD Micro Main Event XVIJuly 31, 2023 | finance.yahoo.comTC BioPharm Maintains Nasdaq ListingJuly 6, 2023 | finance.yahoo.comTC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day PodcastMay 24, 2023 | finance.yahoo.comTC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023March 30, 2023 | finance.yahoo.comTC BioPharm Announces Closing of $5.5 Million Public OfferingMarch 28, 2023 | morningstar.comADRs End Higher, Ambev and TC BioPharm Trade HigherMarch 28, 2023 | finance.yahoo.comTC BioPharm Announces Pricing of $5.5 Million Public OfferingMarch 22, 2023 | markets.businessinsider.comTC BioPharm Unveils Corporate Restructuring Plan; To Cut Up To 30% Of WorkforceMarch 22, 2023 | finance.yahoo.comTC Biopharm Announces Corporate Restructuring, Reduction in OverheadMarch 7, 2023 | finance.yahoo.comTC BioPharm Shifts Focus to FDA Clinical TrialsFebruary 23, 2023 | finance.yahoo.comTC BioPharm Announces Dr. Mike Leek as Chief Technology OfficerSee More Headlines Receive TCBPW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:TCBPW CUSIPN/A CIK1872812 Webwww.tcbiopharm.com Phone44 14 1433 7557FaxN/AEmployees41Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.86 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Bryan L. Kobel (Age 45)CEO & Director Mr. Martin E. Thorp (Age 72)CFO & Director Mr. Christopher CamarraExecutive Vice President of CommunicationsDr. Lauren Bor Ph.D.Head of Commercial Development DivisionKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors TCBPW Stock Analysis - Frequently Asked Questions How have TCBPW shares performed in 2024? TC Biopharm's stock was trading at $0.0325 at the beginning of 2024. Since then, TCBPW shares have decreased by 36.0% and is now trading at $0.0208. View the best growth stocks for 2024 here. How do I buy shares of TC Biopharm? Shares of TCBPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCBPW) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
